Increased deoxycholic acid absorption and gall stones in acromegalic patients treated with octreotide: More evidence for a connection between slow transit constipation and gall stones

Gut

Volumn 54, Issue 5, 2005, Pages 575-578

  Hofmann, A F ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLECYSTOKININ; CHOLESTEROL; DEOXYCHOLIC ACID; GROWTH HORMONE; NITRIC OXIDE; OCTREOTIDE;

ACROMEGALY; BACTERIAL COLONIZATION; BILE; BILE FLOW; BILE SECRETION; CHOLESTEROL METABOLISM; CONSTIPATION; DRUG MECHANISM; GALLSTONE; HEPATOBILIARY SYSTEM; HORMONE RELEASE; HUMAN; INTESTINE ABSORPTION; INTESTINE TRANSIT TIME; ISOTOPE DILUTION ASSAY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ACROMEGALY; CONSTIPATION; DEOXYCHOLIC ACID; GALLSTONES; GASTROINTESTINAL TRANSIT; HUMANS; INTESTINAL ABSORPTION; OCTREOTIDE;

EID: 17644427399     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.048074     Document Type: Review

References (56)

1. Thomas LA, Veysey MJ, Murphy G, et al. Octreotide induced prolongation of colonic transit increases foecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly. Gut 2005;54:630-5.
2. Hussaini SH, Pereira SP, Veysey MJ, et al. The roles of gallbladder emptying and intestinal transit in the pathogenesis of octreotide-induced gallbladder stones Gut 1996;38:775-83.
3. Veysey MJ, Thomas LA, Mallet AI, et al. Prolonged large bowel transit increases serum deoxycholic acid-a risk factor for octreotide-induced gallbladder stones. Gut 1999;44:675-82.
4. Marbach P, Bauer W, Briner U, et al. Structure-function relationships of somatostatin analogs. Horm Res 1988;29:54-8.
5. Melmed S, Casanueva FF, Avagnini F, et al. Acromegaly treatment consensus workshop participants. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054-8.
6. Dowling RH, Hussaini SH, Murhy GM, et al. Gallstones during octreotide therapy. Metabolism 1992;41(suppl 2):22-33.
7. Hussaini SH, Pereira SP, Murphy GM, et al. The composition of octreotide-associated gallbladder stones; response to oral ursodeoxycholic acid. Gut 1995;36:126-32.
8. Hussaini SH, Murphy GM, Kennedy C, et al. The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones. Gastroenterology 1994;107:1503-13.
9. Fromm H, Malavolti M. Bile acid dissolution therapy of gallbladder stones. Baillieres Clin Gastroenterol 1992;6:689-95.
10. Thomas LA, King A, French GL, et al. Cholylglycine hydrolase and 7α-dehydroxylase optimum assay conditions in vitro and caecal enzyme activities ex vivo. Clin Chim Acta 1997;268:61-72.
11. Thomas LA, Bathgate T, Veysey MJ, et al. Mechanism for the transit-induced increase in colonic deoxycholic acid formation in cholesterol cholelithiasis. Gastroenterology 2000;119:806-15.
12. Hofmann AF, Hoffman NE. Measurement of bile acid kinetics by isotope dilution in man. Gastroenterology 1974;67:314-23.
13. Lewis SJ, Heaton KW. Increasing butyrate concentration in the distal colon by accelerating intestinal transit. Gut 1997;41:245-51.
14. Thomas LA, Veysey MJ, Murphy GM, et al. Influence of pH on the phase distribution of nascent deoxycholic acid in fresh human cecal aspirates Am J Physiol 2001;281:G371-4.
15. 2+ ions. J Lipid Res 1992;33:617-26.
16. Hussaini SH, Pereira SP, Murphy GM, et al. Deoxycholic acid influences cholesterol solubilization and microcrystal nucleation time in gallbladder bile. Hepatology 1995;22:1735-44.
17. Van Erpecum KJ, Stolk MFJ, van den Broek AMWC, et al. Bile concentration promotes nucleation of cholesterol monohydrate crystals by increasing the cholesterol concentration in the vesicles. Eur J Clin Invest 1993;23:283-8.
18. Holzbach RT, Marsh M, Olszewski M, et al. Cholesterol solubility in bile: evidence that supersaturated bile is frequent in healthy man. J Clin Invest 1973;52:1467-79.
19. Erlinger S, Chanson P, Dumont M, et al. Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly. A prospective study. Dig Dis Sci 1994;39:2384-8.
20. Olivecrona H, Ericsson S, Angelin B. Growth hormone treatment does not alter biliary lipid metabolism in healthy adult man. J Clin Endocrine Metab 1995;80:1113-17.
21. Heubi JE, Burstein S, Sperling MA, et al. The role of human growth hormone in the regulation of cholesterol and bile acid metabolism. J Clin Endocrinol Metab 1983;57:885-91.
22. Lembke B, Creutzfeld W, Shlesser S, et al. Effect of somatostatin analogue Sandastotin (SMS 201-995) on gastrointestinal, pancreatic, and biliary function and hormone release in normal man. Digestion 1987;36:108-24.
23. Fisher RS, Rock E, Levin G, Malmud L. Effect of somatostatin on gallbladder emptying. Gastroenterology 1987;92:885-90.
24. Sand J, Arvola P, Jantti V, et al. The inhibitory role of nitric oxide in the control of porcine and human sphincter of Oddi activity. Gut 1997;41:75-80.
25. LaRusso NF, Korman MG, Hoffman NE, et al. Dynamics of the enterohepatic circulation of bile acids. Postprandial serum concentrations of conjugates of cholic acid in health, cholecystectomized patients, and patients with bile acid malabsorption. N Engl J Med 1974;291:689-92.
26. LaRusso NF, Hoffman NE, Korman MG, et al. Determinants of fasting and postprandial serum bile acid levels in healthy man. Am J dig Dis 1978;23:385-91.
27. Vinik AI, Strodel WE, Eckhauser FE, et al. Somatostatinomas, PPomas, neuotensinomas. Semin Oncol 1987;14:263-81.
28. De Leo A, Bajetta E, Ferrari L, et al. A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma. Cancer 1996;78:35-42.
29. Hogenauer C, Meyer RI, Netto GJ, et al. Malabsorption due to cholecystokinin deficiency in a patient with autoimmune palyglandular syndrome type I. N Engl J Med 2001;344:270-4.
30. Witt K, Pedersen NT. The long-acting somatostatin analogue SMS 201-995 causes malabsorption. Scand J Gastroenterol 1989;24:1248-52.
31. Bennion LJ, Grundy SM. Risk factors for the development of cholelithiasis in man. N Engl J Med 1978;299:1161-67, 1221-27.
32. Duane WC, Ginsberg RI, Bennion LJ. Effects of fasting on bile acid metabolism and biliary lipid composition in man. J Lipid Res 1976;17:211-19.
33. Shiffman ML, Sugerman HJ, Moore EW. Human gallbladder mucosal function. Effect of concentration and acidification on bile cholesterol and calcium solubility. Gastroenterology 1990;99:1452-9.
34. van Berge Henegouwen GP, Hofmann AF. Nocturnal gallbladder storage and emptying in gallstone patients and healthy subjects. Gastroenterology 1978;75:879-85.
35. Graf GA, Yu L, Li WP, et al. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem 2003;278:48275-82.
36. Gong AY, Tietz PS, Muff MA, et al. Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. Am J Physiol Cell Physiol 2003;284:C1205-14.
37. Marteau P, Chretien Y, Calmus Y, et al. Pharmacologic effect of somatostatin on bile secretion in man. Digestion 1989;42:16-21.
38. John KD, Ballantyne GH, Modlin IM. Octreotide acetate inhibits motility in the rabbit distal colon. Eur Surg Res 1997;29:311-18.
39. Thomas LA, Veysey MJ, French G, et al. Bile acid metabolism by fresh human colonic contents: a comparison of cecal versus foecal samples. Gut 2001;49:835-42.
40. Marcus SN, Heaton KW. Intestinal transit, deoxycholic acid, and the cholesterol saturation of bile: three inter-related factors. Gut 1986;27:550-8.
41. Carulli N, Ponz de Leon M, Loria P, et al. Effect of the selective expansion of cholic acid pool on bile lipid composition: possible mechanism of bile acid induced biliary cholesterol desaturation. Gastroenterology 1981;81:539-46.
42. Berr F, Kullak-Ublick GA, Paumgartner G, et al. 7 alpha-dehydroxylating bacteria enhance deoxycholic acid input and cholesterol saturation of bile in patients with gallstones. Gastroenterology 1996;111:1611-20.
43. Van Erpecum KJ, van Berge-Henegouwen GP. Gallstones: an intestinal disease? Gut 1999;44:435-8.
44. Einarsson C, Hellebrant CG, Axelson M. Effect of treatment with deoxycholic and chenodeoxycholic acid on the hepatic synthesis of cholesterol and bile acids in healthy subjects. Hepatology 2001;33:1189-93.
45. Post SM, Duez H, Gervois PP, Staels B, et al. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol 2001;21:1840-5.
46. Hofmann AF, Grundy SM, Lachin JM, et al and the National Cooperative Gallstone Study Group. Pretreatment biliary lipid composition in white patients with radiolucent gallstones in the National Cooperative Gallstone Study. Gastroenterology 1982;83:738-52.
47. Gustafsson U, Sahlin S, Einarsson C. Biliary lipid composition in patients with cholesterol gallstones and gallstone-free subjects: deoxycholic acid does not contribute to the formation of cholesterol gallstones. Eur J Clin Invest 2000;30:1099-106.
48. LaRusso NF, Szczepanik PA, Hofmann AF, et al. Effect of deoxycholic acid ingestion on bile acid metabolism and biliary lipid secretion in normal subjects. Gastroenterology 1977;72:132-40.
49. Thistle JL, LaRusso NF, Hofmann AF, et al. Different effects of ursodeoxycholic or chenodeoxycholic acid on biliary cholesterol saturation and bile acid metabolism in man: a dose response study. Dig Dis Sci 1982;12:161-8.
50. Lorenzo-Zuniga V, Bartoli R, Planas R, et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 2003;37:551-7.
51. Nordgaard I, Mortensen PB. Digestive processes in the human colon. Nutrition 1995;11:37-45.
52. Pai R, Tarnawski AS, Tran T. Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness. Mol Biol Cell 2004;15:2156-63.
53. Glinghammar B, Inoue H, Rafter JJ. Deoxycholic acid causes DNA damage in colonic cells with subsequent induction of caspases, COX-2 promoter activity and transcription factors NF-kB and AP-1. Carcinogenesis 2002;23:839-45.
54. Debruyne PR, Bruyneel EA, Karaguni IM, et al. Bile acids stimulate invasion and apoptosis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways. Oncogene 2002;21:6740-50.
55. Heaton KW. Review article: epidemiology of gallbladder disease - role of intestinal transit. Aliment Pharmacol Ther 2000;(suppl 2):9-13.
56. Misciagna G, Leoci C, Guerra V, et al. Epidemiology of cholelithiasis in southern Italy. Part II. Risk factors. Eur J Gastroenterol Hepatol 1996;8:585-93.